Noble Financial Has Bullish Forecast for Ocugen Q2 Earnings

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Equities research analysts at Noble Financial raised their Q2 2025 earnings per share (EPS) estimates for Ocugen in a research report issued to clients and investors on Monday, May 12th. Noble Financial analyst R. Leboyer now forecasts that the company will earn ($0.06) per share for the quarter, up from their prior estimate of ($0.08). The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. Noble Financial also issued estimates for Ocugen's Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.24) EPS.

A number of other equities analysts also recently commented on OCGN. Chardan Capital restated a "buy" rating and set a $7.00 target price on shares of Ocugen in a report on Monday, May 12th. HC Wainwright decreased their price objective on Ocugen from $8.00 to $7.00 and set a "buy" rating for the company in a report on Monday, May 12th.

Ocugen Trading Down 2.4%

Shares of Ocugen stock traded down $0.02 during midday trading on Wednesday, reaching $0.74. 777,185 shares of the company's stock traded hands, compared to its average volume of 4,424,277. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The company has a market cap of $216.10 million, a PE ratio of -4.11 and a beta of 4.21. The stock has a 50 day moving average of $0.67 and a 200-day moving average of $0.75. Ocugen has a 12 month low of $0.52 and a 12 month high of $1.98.

Ocugen (NASDAQ:OCGN - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The company had revenue of $1.48 million during the quarter. Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%.

Hedge Funds Weigh In On Ocugen

Institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers boosted its position in shares of Ocugen by 12.9% during the fourth quarter. Rhumbline Advisers now owns 324,475 shares of the company's stock valued at $261,000 after buying an additional 37,034 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Ocugen by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 6,588,407 shares of the company's stock valued at $5,305,000 after buying an additional 309,853 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Ocugen by 12.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 860,244 shares of the company's stock valued at $692,000 after buying an additional 93,288 shares during the last quarter. SG Americas Securities LLC boosted its position in Ocugen by 72.7% in the fourth quarter. SG Americas Securities LLC now owns 152,176 shares of the company's stock worth $123,000 after purchasing an additional 64,080 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in Ocugen in the fourth quarter worth about $40,000. 10.27% of the stock is currently owned by institutional investors.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.